Generated June 2026 from current fund data.
Overview
MRNA is Moderna Inc., the mRNA vaccine and therapeutics company trading as a stock with modest quarterly dividends. MRNY is YieldMax's covered-call ETF wrapping MRNA shares and selling call options against them weekly to generate income. They're the same underlying business, but MRNY's structure prioritizes yield capture through systematic options premium, while MRNA offers traditional equity ownership with minimal distributions.
How they differ
The fundamental difference is structure: MRNA is direct stock ownership; MRNY is a covered-call ETF layering derivatives on top of MRNA holdings. MRNY's 108.67% distribution rate dwarfs MRNA's quarterly dividend by selling weekly call options, extracting premium that gets paid out to shareholders. That aggressive income comes at a cost: MRNY charges a 0.99% expense ratio and accepts the certainty of capped upside (shares get called away if MRNA rises sharply), while MRNA offers unlimited appreciation potential but no meaningful income. MRNY is also much smaller ($84.8M in AUM) and newer (launched June 2024), whereas MRNA is the established direct equity play.
Who each is best for
MRNA: Investors seeking growth-oriented exposure to Moderna's pipeline and commercialization upside, with minimal reliance on current distributions and a willingness to accept equity volatility for long-term capital appreciation.
MRNY: Income-focused investors who own or would consider owning MRNA but want to monetize call premiums weekly, accepting capped gains in exchange for high current yield—and who can tolerate options-related mechanics and potential share assignment.
Key risks to know
* NAV erosion at extreme yields. A 108.67% annualized distribution rate on a $17.13 share price requires continuous call-sale premium to sustain. If implied volatility contracts, call values shrink, distributions may decline sharply, and NAV can erode faster than underlying MRNA appreciation offsets.
* Call assignment caps upside. MRNY's shares are called away if MRNA closes above the strike at expiration. Investors locked into weekly rolls forfeit any rally beyond the strike, turning MRNA's potential appreciation into a mechanical cap—a meaningful tradeoff in a volatile biotech name.
* Concentration risk in single asset. Both tickers tie entirely to Moderna's fortunes. MRNA has product concentration (mRNA platform) and pipeline risk; MRNY amplifies that single-name risk through leverage-like daily management and derivatives mechanics.
* Options volatility and implied-vol dependency. MRNY's yield depends on implied volatility of MRNA options. A sharp drop in IV—whether from MRNA's stabilization or broader market shifts—directly reduces premium captured and thus distributions, independent of MRNA's stock performance.
* ETF liquidity and scale risk. At $84.8M AUM and barely six months old, MRNY has limited trading depth and no performance track record beyond a calm market period. Stress or outflows could widen spreads or force disadvantageous roll adjustments.
Bottom line
If you seek growth and can accept no current income, MRNA offers direct equity exposure without derivative constraints. If you own MRNA and want to harvest option premium regardless of price action, MRNY's weekly distributions appeal—but come with call assignment risk, distribution volatility, and the structural drag of a young, small-cap ETF. Past performance, especially over a six-month window, does not predict how MRNY's distributions or NAV will behave in rising rates or volatile environments.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
